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Background. Irradiation of a larger volume of the target may lead to an increase of the doses delivered to the sur-
rounding organs at risk (OAR) for post-prostatectomy patients with a higher risk of nodal involvement. It was antici-
pated that IMRT significantly improved OAR sparing. The aim of this study was to provide a dosimetric comparison 
between conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) treatment plans for patients 
with prostate cancer irradiated to the prostate bed and pelvic lymph-nodal area.
Materials and methods. The 3D-CRT and IMRT plans were created for ten patients after prostatectomy. The treat-
ment plans were generated for the prostate bed (PTV1) and the pelvic lymph nodes (PTV2). The sum of PTV1 and 
PTV2 was irradiated to a mean dose of 46 Gy in 23 fractions, and additionally PTV1 was irradiated to a mean dose of 
18 Gy in 9 fractions. Target coverage and the doses delivered to the pelvic bones, the rectum, the bladder, the bowel 
bag, and the femurs, were compared between techniques. The Wilcoxon signed-rank test was used to compare the 
dosimetric parameters.
Results. The dosimetric quality of 3D-CRT and IMRT plans were comparable for target coverage (the mean value of 
PTV1 V95%, the mean value of PTV2 V95% all > 99%). The IMRT plans resulted in  significant reductions in the pelvic 
bones V30[%], V40[%], the rectum V40[%], V50[%], V60[%], the bladder V40[%], V50[%], V60[%], the bowel bag V45[cc] 
and the femurs V40[%].
Conclusions. The analysis presented in this paper demonstrates that the IMRT technique reduces the delivered dose 
to the OARs. Most interesting was the possibility of reducing the delivered dose to the pelvic bones and the bowel 
bag. This allowed us to expect a decreased risk of acute hematologic toxicity and acute gastrointestinal toxicity.
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Background
Intensity modulated radiotherapy (IMRT) has become 
a standard among modern treatment techniques. There 
are many publications which demonstrate the benefits of 
IMRT in radiotherapy for patients with prostate cancer [1–9]. 
However, only a few of them have evaluated the feasibility 
of this technique for patients after prostatectomy [10–12]. 
These studies show that IMRT, together with a helical tomo-
therapy (HT), allow for better local tumour control and spare 
organs at risk (OARs).  
For post-prostatectomy patients with a higher risk of 
nodal involvement irradiation of the pelvic lymph nodes 
may improve the treatment outcome by potentially eradi-
cating nodal micrometastases [13]. 
On the other hand, irradiation of a larger volume of the 
target may lead to an increase of the doses delivered to 
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surrounding OARs, including the rectum, the bladder, the 
bowel bag, the femurs, and the pelvic bones. Clinical inves-
tigation conducted by Alongi et al. [14] showed that IMRT 
and HT significantly reduce the risk of acute genito-urinary 
and gastrointestinal toxicity when compared to conformal 
techniques (3D-CRT). However, in this paper, the dosimetric 
parameters of dose distribution have not been considered 
and the dose delivered to the pelvic bones was not taken 
into account. 
The dose to the pelvic bones is a surrogate of the dose 
delivered to the bone marrow, which is an important factor 
in the treatment process. It is anticipated that IMRT signifi-
cantly improves OAR sparing, including the pelvic bones, 
while maintaining a similar level of the target coverage when 
compared to 3D-CRT for the irradiation of the prostate bed 
and the pelvic lymph nodes.
The aim of this study was to compare the quality of the 
plans prepared with IMRT and 3D-CRT techniques in terms 
of the dosimetric parameters of dose distribution.
Materials and methods
Treatment plans for 10 patients treated between 2012 
and 2014 were analysed.
The clinical indications for radiotherapy were as follows:
 — tumour stage: pT3a / b — exceeding the prostate and/ 
/or infiltration of the seminal vesicle;
 — positive surgical margin (R1);
 — lymph node involvement N (+);
 — PSA > 0.2 ng/ml at least 5 weeks after surgery.
The patients were given a pharmaceutical treatment 
7 days prior to a planning CT scan, in order to prevent bowel 
distention. The patients were asked to drink 500 ml of water 
30 minutes prior to the CT scan and then before each irra-
diation session. The patients were scanned using a contrast 
computed tomography (3 mm slice thickness) in the supine 
position with a knee support and with their hands resting 
on their chest. Planning CT scans were obtained from the 
mid-level L4 up to 5 cm below the ischial tuberosities. 
CTV1 included the prostate bed depending on the di-
agnosis with or without the seminal vesicles (classification 
T3a — covered base of seminal vesicle, classification T3b 
— covered 2/3 of seminal vesicle). PTV1 was created by 
extending the CTV1 by a 1 cm margin.
CTV2 included the pelvic lymph nodes and was drawn 
starting from the L5/S1 level up to the upper edge of the 
symphysis pubis. The external iliac nodes were drawn up to 
the top of the femoral heads. CTV2 was then grown isotropi-
cally by 7 mm to create PTV2. 
The following at risk organs were contoured: the rectum, 
the bladder, the right and left femurs (femur L/R), the bowel 
bag, the pelvic bones. The left and right femurs, the bowel 
bag, the rectum and the bladder were drawn according to the 
recommendations of the RTOG pelvis atlas [15]. The bowel bag 
was cropped from PTV1 and PTV2 with no margin. The pelvic 
bones were delineated from the level of the ischial tuberosities 
up to the tops of the upper iliac, including the femurs.
The radiotherapy was delivered with a mean dose to 
PTV1 of 64 Gy and with a mean dose to PTV2 of 46 Gy. The 
treatment was delivered in two phases. The prescribed dose 
of 46 Gy with a fractionation regime of 2 Gy per fraction was 
initially delivered to PTV1 and PTV2. During the second part, 
PTV1 was irradiated to 18 Gy in 9 fractions.
Individual 3D-CRT and IMRT treatment plans were de-
signed for each patient using a commercial treatment plan-
ning system (Eclipse ver. 6.5, Varian Medical Systems, Inc.). 
The calculations were performed using the AAA algorithm 
(Anisotropic Analytical Algorithm, Ver. 10.0.28). The 3D-CRT 
plans were created according to our clinical protocol. The 
three field technique was used with 15 MV photon beams 
and gantry angles of 0°, 90°, 270°. Appropriate AP wedges 
were applied to the lateral beams and the anterior beam was 
split to two separate beams as shown in Figure 1. 
Figure 1. Field shapes for beams in the first stage of treatment. Gantry angle 0º. PTV1 and PTV2 are shown in red
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Sliding window IMRT plans were created using 5 pho-
ton beams with an energy of 6 MV (gantry angles of 0º, 
72º, 144º, 216º, 288º). A small modification to the gantry 
angle was allowed in order to spare the femoral heads. 
A collimator angle of 3º was chosen to minimise the overlap 
of interleaf leakage.
The PTV planning objective was to deliver more than 
95% of the prescribed dose to a minimum of 98% of the 
target volume. The dose volume histograms were evaluated 
for both techniques for the PTV and for the organs at risk 
alternatively. Using the recommendations of the Quantita-
tive Analysis of Normal Tissue Effects in the Clinic study 
(QANTEC) [16], the indices listed in Table I obtained for 
the 3D-CRT and the IMRT techniques were compared. The 
Wilcoxon signed-rank test was used and the p-values were 
calculated (Tab. I).
Results
According to this study, the mean value of PTV1 V95% 
and the mean value of PTV2 V95% for the 3D-CRT and the 
IMRT plans were comparable. The average volume of PTV1 
receiving at least 95% of the prescribed dose was 99.2% and 
99.7% for the 3D-CRT and the IMRT techniques, respectively. 
The average volume of PTV2, receiving at least 95% of the 
prescribed dose, was 99.0% and 99.9% for the 3D-CRT and 
the IMRT techniques, respectively. The average minimum 
doses delivered to the prostate bed were 59.9 Gy and 59.2 Gy 
for the 3D-CRT and the IMRT, respectively. The average pros-
tate bed maximum doses were 65.2 Gy and 66.2 Gy for the 
3D-CRT and the IMRT techniques, respectively. The lymph 
nodes received a patient-average minimum dose of 42.5 Gy 
and 42.4 Gy and a patient average maximum dose of 62.3 Gy 
and 61.8 Gy for the 3D-CRT and the IMRT, respectively. 
All these differences were not statistically significant 
(p-value > 0.05).
The IMRT plans resulted in a significant reduction of 
doses delivered to the OARs (Table II). Due to anatomical 
differences between patients which cause large differences 
in the volumes of the bowel bag receiving a dose 45Gy or 
higher, a patient-average value V45[cc] was not calculated 
and not compared in this study (Tab. II).
The average cumulative dose-volume histograms illus-
trating the differences between both techniques are shown 
in Figure 2. Due to the symmetry in patient anatomy, only 
results for the left femur were presented. 
Discussion 
The dose distribution in PTV1 and PTV2 were similar in 
3D-CRT and IMRT plans. DVH analysis and the Wilcoxon test 
for the femurs V40Gy showed that the IMRT technique is safer 
for femurs than the 3D-CRT. Some authors recommend dose 
constraint for the femur to be V50Gy < 5% [17]. However, in 
this study, these structures were not exposed to such high 
doses and therefore V40Gy was selected for analysis instead. 
The difference between the population average values of 
the V40Gy3D-CRT and V40GyIMRT (V40Gy3D-CRT–V40GyIMRT) were 
23.13% and 27.4% for the left and the right femur, respec-
tively. These results demonstrate that the IMRT technique 
significantly reduces the volume of femurs receiving a dose 
of 40Gy and higher.
Another benefit of using the IMRT technique is improved 
sparing of the pelvic bones. The flat bones of the pelvis 
include red marrow which produces white blood cells, eryth-
rocytes and platelets. The irradiation of the pelvic area, and 
thus of the pelvic bones can influence the hematopoietic 
function of red bone marrow. Mell et al. [18] report a de-
crease of haematological toxicity after reducing the dose 
delivered to the bone marrow for patients with rectal cancer. 
The ability to isolate the structure of bone marrow using PET 
for patients with gynaecological diseases was analysed by 
McGuire et al. [19]. The active bone marrow was regarded 
as an important critical organ. During irradiation of patients 
with a higher risk of nodal involvement, the pelvic bones 
were included in the treatment area. Analysis of 3D-CRT 
and IMRT plans demonstrates that average differences 
(V40Gy3D-CRT–V40GyIMRT) and (V30Gy3D-CRT–V30GyIMRT) for pelvic 
bones were 8.02% and 9.15%, respectively.
Table I. The dose distribution indices used for comparison
OAR Analysed value
Femur L and femur R V40Gy[%]
Pelvic bones V30Gy[%], V40Gy[%]
Bladder V40Gy[%], V50Gy[%], V60Gy[%]
Rectum V40Gy[%], V50Gy[%], V60Gy[%]
Bowel bag V45Gy[cc]
Table II. The average differences between values Vxx obtained using 
3D-CRT and IMRT techniques, p-values are based on the Wilcoxon signed-
rank test. Vxx is the volume receiving a dose of xxGy or higher
OAR Vxx p-value Average difference  
Vxx3D-CRT – VxxIMRT
Femur L V40Gy[%] 0.007 23.13
Femur R V40Gy[%] 0.005 27.74
Pelvic bones
V30Gy[%] 0.007 9.183
V40Gy[%] 0.005 8.022
Bladder
V40Gy[%] 0.005 8.738
V50Gy[%] 0.007 6.821
V60Gy[%] 0.007 4.088
Rectum
V40Gy[%] 0.028 6.277
V50Gy[%] 0.005 8.002
V60Gy[%] 0.005 4.604
Bowel bag V40Gy[cc] 0.005 –
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The QUANTEC recommends the following constrains: for 
the bladder (V65Gy < 50%) and for the rectum (V50Gy < 50%). 
Regardless of the technique, the doses received by the blad-
der and the rectum were significantly lower. However, better 
protection of the bladder and of the rectum was noticed in 
the 40–60 Gy dose range for IMRT plans.
According to the QUANTEC recommendations, the 
bowel bag value of V45Gy[cc] was analysed. The Wilcoxon 
signed-rank test showed statistically significant differences 
in the bowel bag V45Gy[cc] between the techniques studied. 
These results are consistent with the work by Alongi et al. 
[14], which is based on clinical studies. Alongi noticed a re-
duction in toxicity to the bowel bag for the IMRT technique. 
Conclusions
This study demonstrated that the IMRT technique for 
post-prostatectomy patients with a higher risk of nodal 
involvement is more advantageous than the 3D conformal 
technique. The IMRT technique resulted in better OAR spar-
ing, especially for the pelvic bones. The dose distributions 
in all PTVs were similar to each other. The IMRT technique 
is more time consuming, due to the complexity of the 
planning process and of treatment verification. However, 
better sparing from the IMRT technique resulted in the 
introduction of the IMRT technique into clinical practice 
at our institute. 
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